1. Academic Validation
  2. Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinase

Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinase

  • J Med Chem. 2011 Apr 14;54(7):2255-65. doi: 10.1021/jm101423y.
David M Goldstein 1 Michael Soth Tobias Gabriel Nolan Dewdney Andreas Kuglstatter Humberto Arzeno Jeffrey Chen William Bingenheimer Stacie A Dalrymple James Dunn Robert Farrell Sandra Frauchiger JoAnn La Fargue Manjiri Ghate Bradford Graves Ronald J Hill Fujun Li Renee Litman Brad Loe Joel McIntosh Daniel McWeeney Eva Papp Jaehyeon Park Harlan F Reese Richard T Roberts David Rotstein Bong San Pablo Keshab Sarma Martin Stahl Man-Ling Sung Rebecca T Suttman Eric B Sjogren Yunchou Tan Alejandra Trejo Mary Welch Paul Weller Brian R Wong Hasim Zecic
Affiliations

Affiliation

  • 1 Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304, United States. David-M.Goldstein@roche.com
Abstract

The development of a new series of p38α inhibitors resulted in the identification of two clinical candidates, one of which was advanced into a phase 2 clinical study for rheumatoid arthritis. The original lead, an Lck Inhibitor that also potently inhibited p38α, was a screening hit from our kinase inhibitor library. This manuscript describes the optimization of the lead to p38-selective examples with good pharmacokinetic properties.

Figures
Products